Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds targeting complement-mediated and other rare diseases. The company operates at the commercial stage, having brought two products to market: EMPAVELI (pegcetacoplan), approved for paroxysmal nocturnal hemoglobinuria, and SYFOVRE (pegcetacoplan), approved for geographic atrophy secondary to age-related macular degeneration. Both therapies represent the company's core complement inhibition platform technology.

Beyond its marketed products, Apellis maintains an active pipeline addressing multiple indications. EMPAVELI is in development for C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function. APL-3007, a small interfering RNA candidate, targets geographic atrophy through a distinct mechanism. The company is also developing APL-9099, a neonatal Fc receptor inhibitor in preclinical stages, and conducting research in gene editing through a collaboration with Beam Therapeutics focused on base editing technology for complement-driven diseases.

Apellis operates with approximately 733 full-time employees and is headquartered in Waltham, Massachusetts. The company maintains a collaboration and license agreement with Swedish Orphan Biovitrum AB for development and commercialization rights to pegcetacoplan, representing a significant component of its revenue strategy. The company was incorporated in Delaware in 2009.